Status:
COMPLETED
Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases
Lead Sponsor:
University of Leeds
Collaborating Sponsors:
National Cancer Institute (NCI)
Massachusetts General Hospital
Conditions:
Colon Cancer Liver Metastasis
Eligibility:
All Genders
18+ years
Brief Summary
A significant proportion of patients who undergo liver surgery to remove bowel cancer that has spread to the liver (metastases) develop disease recurrence and die from the disease. The EMT2 study (NCT...
Detailed Description
Despite advance in the diagnosis and treatment of colorectal cancer (CRC), it remains the second most common cause of cancer-related death in the US and the UK. The majority of deaths from CRC are rel...
Eligibility Criteria
Inclusion
- Only individuals who have already been enrolled in the EMT2 trial are eligible for inclusion in the biospecimen collection study.
Exclusion
- There are NO exclusions for entry to the biospecimen collection study if an individual has already been recruited to the EMT2 trial.
Key Trial Info
Start Date :
September 16 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2024
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT04682665
Start Date
September 16 2021
End Date
July 31 2024
Last Update
December 4 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
St James's University Hospital
Leeds, United Kingdom
2
University of Liverpool
Liverpool, United Kingdom